TipRanks
TG Therapeutics (CH:NKB2)
:NKB2
Switzerland Market
NKB2
TG Therapeutics
RESEARCH TOOLSreports

TG Therapeutics (NKB2) Stock Forecast & Price Target

0 Followers
See the Price Targets and Ratings of:

NKB2 Analyst Ratings

Moderate Buy
6Ratings
Moderate Buy
5 Buy
0 Hold
1 Sell
Based on 6 analysts giving stock ratings to
TG
Therapeutics
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

NKB2 Stock 12 Month Forecast

Average Price Target

―
Based on 6 Wall Street analysts offering 12 month price targets for TG Therapeutics in the last 3 months. The average price target is CHF57.36 with a high forecast of CHF71.32 and a low forecast of CHF17.41. The average price target represents a ― change from the last price of ―.
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
Highest Price TargetCHF71.32Average Price TargetCHF57.36Lowest Price TargetCHF17.41
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
H.C. Wainwright Analyst forecast on CH:NKB2
Emily Bodnar
H.C. Wainwright
H.C. Wainwright
CHF64.68
Buy
―
Reiterated
09/21/26
TG Therapeutics (TGTX) Receives a Buy from H.C. Wainwright
B. Riley Securities Analyst forecast on CH:NKB2
William Wood
B. Riley Securities
B. Riley Securities
CHF71.32
Buy
―
Reiterated
09/02/26
B. Riley Securities Remains a Buy on TG Therapeutics (TGTX)
J.P. Morgan Analyst forecast on CH:NKB2
Brian Cheng
J.P. Morgan
J.P. Morgan
CHF53.9→CHF59.71
Buy
―
Reiterated
08/10/26
J.P. Morgan Reaffirms Their Buy Rating on TG Therapeutics (TGTX)
Bank of America Securities Analyst forecast on CH:NKB2
Alec Stranahan
Bank of America Securities
Bank of America Securities
CHF16.59→CHF17.41
Sell
―
Reiterated
08/05/26
Analysts Offer Insights on Healthcare Companies: TG Therapeutics (NASDAQ: TGTX), Syndax Pharmaceuticals (NASDAQ: SNDX) and DaVita (NYSE: DVA)
TD Cowen Analyst forecast on CH:NKB2
Tara Bancroft
TD Cowen
TD Cowen
CHF62.2
Buy
―
Reiterated
08/03/26
Briumvi’s Rapid Commercial Momentum and Upward Sales Guidance Underpin Bancroft’s Buy Rating
Jefferies Analyst forecast on CH:NKB2
Roger Song
Jefferies
Jefferies
CHF68.83
Buy
―
Reiterated
07/14/26
Analysts Conflicted on These Healthcare Names: Biogen (NASDAQ: BIIB) and TG Therapeutics (NASDAQ: TGTX)
Goldman Sachs Analyst forecast on CH:NKB2
Corinne Johnson
Goldman Sachs
Goldman Sachs
CHF34
Hold
―
Reiterated
06/03/26
Corinne Johnson Reiterates Hold Rating on Briumvi Developer, Keeps Price Target Unchanged at $41 Amid Long-Term Potential and Execution Risks
Citi Analyst forecast on CH:NKB2
Eric Joseph
Citi
Citi
CHF38.15→CHF40.63
Buy
―
Reiterated
11/03/25
TG Therapeutics price target raised to $49 from $46 at JPMorganTG Therapeutics price target raised to $49 from $46 at JPMorgan
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
H.C. Wainwright Analyst forecast on CH:NKB2
Emily Bodnar
H.C. Wainwright
H.C. Wainwright
CHF64.68
Buy
―
Reiterated
09/21/26
TG Therapeutics (TGTX) Receives a Buy from H.C. Wainwright
B. Riley Securities Analyst forecast on CH:NKB2
William Wood
B. Riley Securities
B. Riley Securities
CHF71.32
Buy
―
Reiterated
09/02/26
B. Riley Securities Remains a Buy on TG Therapeutics (TGTX)
J.P. Morgan Analyst forecast on CH:NKB2
Brian Cheng
J.P. Morgan
J.P. Morgan
CHF53.9→CHF59.71
Buy
―
Reiterated
08/10/26
J.P. Morgan Reaffirms Their Buy Rating on TG Therapeutics (TGTX)
Bank of America Securities Analyst forecast on CH:NKB2
Alec Stranahan
Bank of America Securities
Bank of America Securities
CHF16.59→CHF17.41
Sell
―
Reiterated
08/05/26
Analysts Offer Insights on Healthcare Companies: TG Therapeutics (NASDAQ: TGTX), Syndax Pharmaceuticals (NASDAQ: SNDX) and DaVita (NYSE: DVA)
TD Cowen Analyst forecast on CH:NKB2
Tara Bancroft
TD Cowen
TD Cowen
CHF62.2
Buy
―
Reiterated
08/03/26
Briumvi’s Rapid Commercial Momentum and Upward Sales Guidance Underpin Bancroft’s Buy Rating
Jefferies Analyst forecast on CH:NKB2
Roger Song
Jefferies
Jefferies
CHF68.83
Buy
―
Reiterated
07/14/26
Analysts Conflicted on These Healthcare Names: Biogen (NASDAQ: BIIB) and TG Therapeutics (NASDAQ: TGTX)
Goldman Sachs Analyst forecast on CH:NKB2
Corinne Johnson
Goldman Sachs
Goldman Sachs
CHF34
Hold
―
Reiterated
06/03/26
Corinne Johnson Reiterates Hold Rating on Briumvi Developer, Keeps Price Target Unchanged at $41 Amid Long-Term Potential and Execution Risks
Citi Analyst forecast on CH:NKB2
Eric Joseph
Citi
Citi
CHF38.15→CHF40.63
Buy
―
Reiterated
11/03/25
TG Therapeutics price target raised to $49 from $46 at JPMorganTG Therapeutics price target raised to $49 from $46 at JPMorgan
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
DFTXDefinium Therapeutics
OVIDOvid Therapeutics
ACHVAchieve Life Sciences
WSTWest Pharmaceutical Services
OMCLOmnicell
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering TG Therapeutics

3 Months
Emily BodnarH.C. Wainwright
Success Rate
9/11 ratings generated profit
82%
Average Return
+16.20%
Copying Emily Bodnar's trades and holding each position for 3 Months would result in 81.82% of your transactions generating a profit, with an average return of +16.20% per trade.
1 Year
Emily BodnarH.C. Wainwright
Success Rate
11/11 ratings generated profit
100%
Average Return
+50.97%
Copying Emily Bodnar's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +50.97% per trade.
2 Years
Tara BancroftTD Cowen
Success Rate
14/14 ratings generated profit
100%
Average Return
+67.98%
Copying Tara Bancroft's trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +67.98% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

NKB2 Analyst Recommendation Trends

Rating
May 26
Jun 26
Jul 26
Aug 26
Sep 26
Strong Buy
4
6
7
7
5
Buy
2
3
7
6
7
Hold
3
4
3
1
0
Sell
1
0
0
0
0
Strong Sell
1
2
2
3
2
total
11
15
19
17
14
In the current month, NKB2 has received 12 Buy Ratings, 0 Hold Ratings, and 2 Sell Ratings. NKB2 average Analyst price target in the past 3 months is 57.36.
Each month's total comprises the sum of three months' worth of ratings.

NKB2 Financial Forecast

NKB2 Earnings Forecast

Next quarter’s earnings estimate for NKB2 is CHF0.30 with a range of CHF0.16 to CHF0.51. The previous quarter’s EPS was CHF0.04. NKB2 beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year NKB2 has Performed in-line its overall industry.
Next quarter’s earnings estimate for NKB2 is CHF0.30 with a range of CHF0.16 to CHF0.51. The previous quarter’s EPS was CHF0.04. NKB2 beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year NKB2 has Performed in-line its overall industry.

NKB2 Sales Forecast

Next quarter’s sales forecast for NKB2 is CHF203.60M with a range of CHF192.65M to CHF211.74M. The previous quarter’s sales results were CHF199.57M. NKB2 beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year NKB2 has Performed in-line its overall industry.
Next quarter’s sales forecast for NKB2 is CHF203.60M with a range of CHF192.65M to CHF211.74M. The previous quarter’s sales results were CHF199.57M. NKB2 beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year NKB2 has Performed in-line its overall industry.

NKB2 Stock Forecast FAQ

What is CH:NKB2’s average 12-month price target, according to analysts?
Based on analyst ratings, TG Therapeutics’s 12-month average price target is 57.36.
    What is CH:NKB2’s upside potential, based on the analysts’ average price target?
    Currently there's no upside potential for CH:NKB2, based on the analysts’ average price target.
    Can I see which stocks the top-ranking analysts are rating?
    Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
      How can I follow the stock ratings of top Wall Street analysts?
      Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
        Is TG Therapeutics a Buy, Sell or Hold?
        TG Therapeutics has a consensus rating of Moderate Buy, which is based on 5 buy ratings, 0 hold ratings and 1 sell ratings.
          What is TG Therapeutics’s share price target?
          The average share price target for TG Therapeutics is 57.36. This is based on 6 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
          The highest analyst share price target is CHF71.32 ,and the lowest forecast is CHF17.41. The average share price target represents N/A Increase from the current price of N/A.
            What do analysts say about TG Therapeutics?
            TG Therapeutics’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 6 Wall Streets Analysts.
              How can I buy shares of TG Therapeutics?
              To buy shares of CH:NKB2, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.